ARFs were initially identified as activators of cholera toxin ADP-ribosyl transferase activity towards the ␣ subunit of the heterotrimeric G protein G s . There are six mammalian ARFs, which are largely soluble but can bind to membranes in a regulated and GTP-dependent manner. ARFs play an essential role in intracellular membrane traffic, and have been implicated in both ER-to-Golgi and intra-Golgi vesicle transport. Reconstitution studies using mammalian systems have demonstrated that ARF1 regulates the assembly of the coat protein complex -the coatomer or COP -which controls the budding of transport vesicles from Golgi cisternae [4, 5] and presumably also from ER membranes. Why there are multiple ARFs is poorly understood, but their existence is presumably important; ARF6, for example, localizes to the plasma membrane and regulates receptor-mediated endocytosis [6] .
Rho family proteins play dynamic roles in the regulation of the actin cytoskeleton, thereby controlling various aspects of cell morphology and motility, depending on the particular Rho protein involved. Thus, Rac is required for membrane ruffling and Rho for formation of stress fibers, and Cdc42 regulates the formation of actin-containing microspikes called filopodia [7] . The effects of Rho proteins in microinjected cells occur on a time scale that is too short to involve alterations in gene expression, indicating that these events must be controlled through other regulatory pathways. Thus, Rho proteins, like ARFs, regulate complex processes in cells and in both cases the precise steps and mechanisms involved have been unclear.
That PLD is activated following agonist stimulation has been observed in numerous cell types and with a wide variety of ligands acting via G-protein-coupled receptors or receptor tyrosine kinases. While investigating the mechanism of PLD activation, several groups observed PLD activities in tissues and cell lines that showed guaninenucleotide dependence, which was subsequently shown to be mediated by members of the ARF and Rho families. Two groups used different approaches to identify ARF as a GTP-dependent regulator of PLD activity [8, 9] . Their observations were initially made using HL-60 cells as the source of PLD activity, but PLD enzymes with similar sensitivity to ARF stimulation (presumably identical or closely related enzymes) are expressed in other tissues. The GTP-dependent activation of PLD in neutrophils is apparently mediated by Rho [10] ; furthermore, two Rhorelated G proteins, Rac1 and Cdc42, can also stimulate several mammalian PLD activities independently of (and synergistically with) other regulators [11, 12] .
We have recently reported [13] the cloning and expression of the human gene encoding PLD1, a G-protein-regulated PLD. ARF1, and the Rho proteins RhoA, Rac1 and Cdc42, all activate purified PLD1; the purified enzyme can also be activated by protein kinase C␣ in a novel, kinase-independent manner. The G-protein activators are approximately equipotent, and the three classes of regulators -ARF, Rho and PKC -activate PLD1 synergistically, suggesting that they interact with different sites on the enzyme (our unpublished data). Several lines of evidence have suggested the existence of additional mammalian PLDs (reviewed in [14] ), and our group has recently identified a second mammalian PLD, PLD2, which, like PLD1, requires phosphatidylinositol 4,5-bisphosphate (PIP 2 ) for activity in vitro (unpublished data). Mammalian tissues also contain PIP 2 -independent PLD activities which are stimulated by fatty acids such as oleate [15] . It is not known how many mammalian PLD enzymes there are, though our molecular studies [13] , which have revealed the existence of a PLD multigene family, should help clarify this important issue.
What is the function of PLD-generated PA?
Understanding the role of PLD in cellular regulation by the ARF and Rho proteins will require identification of the cellular targets and functions of its reaction product, PA.
PA can clearly be metabolized to generate both intracellular and extracellular messengers -diacylglycerol, arachidonic acid and lysophosphatidic acid (reviewed in [14] ) -but it is beginning to appear equally likely that it is also an intracellular mediator in its own right. For example, several identified (Raf and certain PKC isoforms) and unidentified protein kinases have been reported to be activated by PA in vitro [16] , although the physiological importance of this type of regulation requires further study [3] .
As no selective PLD inhibitors have been discovered, attempts to generate direct evidence supporting in vivo roles for PLD-generated PA have entailed the direct administration of PA itself to cells, or the use of primary alcohols which are used as substrates by PLD for a transphosphatidylation reaction which generates phosphatidylalcohols instead of PA. Exogenously added PA has been shown to increase, and primary alcohols to inhibit, actin polymerization leading to stress-fiber formation in endothelial cells, suggesting a role for PLD as a mediator of cytoskeletal reorganization [17] . Primary alcohols have also been used to demonstrate that secretion by HL-60 cells and neutrophils is blocked when PA production is inhibited, supporting the hypothesis that PLD plays a role in secretion [18, 19] .
Caveats should be applied, however, to the interpretation of both of these experimental approaches. PA is normally produced intracellularly by PLD, and it is not clear that exogenously applied PA exerts its actions through normal physiological pathways (as opposed, for example, to stimulating receptors on the cell surface, as lysophosphatidic acid is known to do). And although phosphatidylalchohols appear to be metabolically inert, they may nonetheless activate some PA-dependent processes to an unknown extent. Moreover, the relatively high concentrations of alcohols used in these types of experiment may influence these or other cellular responses through different mechanisms.
The role of PLD1 in ARF and Rho-regulated processes
Given the evidence presented above, it has been tempting to speculate that PLD activation by ARF and Rho reflects roles for distinct PLDs in separate pathways -secretion and signal transduction, respectively. The finding that PLD1 is regulated by both ARF and Rho, however, supports a blurring of this distinction and suggests that the two processes may be more integrated than previously recognized. Several lines of evidence support this idea. For example, most ARF is found in the cytosol in HL-60 cells [20] ; immediately after stimulation with a ligand agonist (fMet-Leu-Phe), however, much of the cytosolic ARF becomes membrane-bound in the Golgi apparatus. This suggests that ARF should be viewed as a participant in the signal transduction process, and that secretion in this instance is a regulated consequence of specific agoniststimulated events.
Rothman and colleagues [4] reported that coatomer assembly can be reconstituted in washed Golgi membrane preparations with the addition of just ARF and coatomer. It is likely, however, that PLD was present in these experiments, as it is tightly associated with membranes and present in significant amounts in the Golgi apparatus [21] . Sternweis, Roth and colleagues [21, 22] have begun to establish that ARF-activated PLD does indeed have an important role in intracellular protein traffic. They have found that ARF-activated PLD is enriched in Golgi membranes, and provided several lines of evidence that PA formed through ARF stimulation of PLD plays an important role in coatomer binding. This suggests the model shown in Figure 1 , in which activation of Golgi-membrane-associated PLD1 by ARF leads to recruitment of the cytosolic coatomer complex, and consequent alterations in membrane structure leading to vesicle budding.
The synergistic effect of Rho on ARF stimulation of PLD1 activity in vitro suggests that this enzyme may act as an integrative regulator of both constitutive secretion, presumably under the control of ARF, and receptor-regulated PLD1-and ARF-dependent formation of coated vesicles. PLD1 participates in the 'priming' step of coated vesicle formation by catalyzing hydrolysis of PC to produce PA, which, perhaps acting in concert with ARF, results in coatomer binding to the membrane surface (possibly mediated by a putative 'coatomer receptor'). Coatomer assembly then results in deformation of the membrane surface (vesiculation), leading to bud formation and release of a coated vesicle (budding). We suggest that activation of PLD1 by ARF and Rho (and PKC) links this process of coated-vesicle formation to activation of cell-surface receptors. (Adapted from [22] .) increases in secretion in response to activation by Rho and possibly PKC. In support of this is evidence that Rho, Rac and Cdc42 play a role in enhancing regulated secretion of interleukin 2 by T cells, and in ensuring that this secretion takes place in a polarized manner (towards the immune cell intended to be the beneficiary of the secreted interleukin) [23] . ARF-dependent secretion from permeabilized HL-60 cells, and ARF-mediated PLD activation, are greatly potentiated by pretreating the cells with phorbol esters, supporting the idea that a synergistic collaboration by other PLD activators, in this instance PKC␣, leads to increased secretion [24] . Based on the synergistic activation described above, PLD1 is a good candidate to be the mediator of this process.
PLD activation by ARF and by the Rho proteins may, therefore, reflect two different aspects of the same physiological response: cytoskeletal reorganization leading to cellular polarization and then temporally and spatially regulated secretion. We suggest that PLD1 is uniquely positioned to receive and integrate different kinds of extracellular and intracellular signals initiated by activation of Rho and ARF, and to transduce them to generate lipid-derived molecules that, in turn, mediate cell-specific responses involving secretion, and perhaps related changes in cell morphology and motility.
Future questions
Several important pieces of this puzzle are still missing. How are the ARF and Rho proteins activated (and deactivated) and do they couple cell-surface receptors to PLD activation? Presumably these processes involve a number of accessory proteins, but the mechanisms involved are not known. What is the function of PLD-generated PA? Does this lipid exert its effects by changing the structure or surface charge of membranes -suggested to be the mechanism by which ARF-activated PLD regulates coatomer binding and vesicle budding -or does it act through specific protein targets? In what cellular compartments does PLD1 operate? Given the complex regulation of PLD1 observed in vitro, perhaps the enzyme is expressed in different compartments where different modes of regulation predominate. The suggestion that ARF-dependent PLD1 activation in the Golgi apparatus generates PA for coated-vesicle formation does not preclude the possibility that PKC and/or Rho-dependent activation of PLD1 at different sites could have other consequences. What is the role of the other PLD isoforms, such as PLD2? With the availability of PLD-encoding cDNAs, recombinant proteins and isoenzyme-selective antibodies, answers to many of these questions should be forthcoming.
